Another Major Milestone | First Class 1.1 Innovative Traditional Chinese Medicine of the New Year Receives IND Approval in China

Recently, according to the official website of the Center for Drug Evaluation (CDE), the Class 1.1 innovative traditional Chinese medicine (TCM) Qingxue Baidu Pills successfully obtained the Notification of Approval for Drug Clinical Trials in China.

All pharmaceutical research and development work for the project was completed by Hunan Yineng Pharmaceutical Co., Ltd. under the commission of Jiangsu Zhongyong Hongrui Pharmaceutical Co., Ltd..

This achievement once again demonstrates Yineng Pharmaceutical’s strong capabilities in innovative TCM drug development and highlights the company’s continuous success in helping partners secure national clinical trial approvals.

Qingxue Baidu Pills: Innovative TCM for Herpes Zoster-Related Pain

Qingxue Baidu Pills are designed to provide:

• Heat-clearing and dampness-removing effects
• Blood-cooling and detoxifying functions
• Swelling reduction and pain relief

The drug is mainly intended for the treatment of pain caused by herpes zoster (shingles) associated with liver-gallbladder damp-heat syndrome and fire-toxin accumulation in traditional Chinese medicine theory. It may also help accelerate the healing of skin lesions.

Target Symptoms Include:

• Bright red skin rashes
• Clustered blisters
• Burning pain and skin inflammation
• Bitter taste in the mouth and dry throat
• Irritability
• Dry stool

(Edited by Professor Yi)

Media Contact
Company Name: Hunan Yineng Biopharmaceuticals Co., Ltd.
Email: Send Email
Country: China
Website: https://www.medgencetec.com/